Histone deacetylase inhibitors

Advancing therapeutic strategies in hematological and solid malignancies

Leigh Ellis, Roberto Pili

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents.

Original languageEnglish (US)
Pages (from-to)2441-2469
Number of pages29
JournalPharmaceuticals
Volume3
Issue number8
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Hematologic Neoplasms
Histone Deacetylases
Autophagy
Apoptosis
Angiogenesis Inhibitors
Therapeutics
Epigenomics
Neoplasms
Carcinogenesis
Drug Therapy

Keywords

  • Angiogenesis
  • Apoptosis
  • Autophagy
  • Cancer
  • Clinical trial
  • Epigenetic therapy
  • Epigenetics
  • HDAC
  • HDAC inhibitors
  • Pre-clinical

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Histone deacetylase inhibitors : Advancing therapeutic strategies in hematological and solid malignancies. / Ellis, Leigh; Pili, Roberto.

In: Pharmaceuticals, Vol. 3, No. 8, 2010, p. 2441-2469.

Research output: Contribution to journalReview article

@article{84a2312caa8b4c369ca7545183fd8548,
title = "Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies",
abstract = "Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents.",
keywords = "Angiogenesis, Apoptosis, Autophagy, Cancer, Clinical trial, Epigenetic therapy, Epigenetics, HDAC, HDAC inhibitors, Pre-clinical",
author = "Leigh Ellis and Roberto Pili",
year = "2010",
doi = "10.3390/ph3082441",
language = "English (US)",
volume = "3",
pages = "2441--2469",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - Histone deacetylase inhibitors

T2 - Advancing therapeutic strategies in hematological and solid malignancies

AU - Ellis, Leigh

AU - Pili, Roberto

PY - 2010

Y1 - 2010

N2 - Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents.

AB - Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents.

KW - Angiogenesis

KW - Apoptosis

KW - Autophagy

KW - Cancer

KW - Clinical trial

KW - Epigenetic therapy

KW - Epigenetics

KW - HDAC

KW - HDAC inhibitors

KW - Pre-clinical

UR - http://www.scopus.com/inward/record.url?scp=77955581767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955581767&partnerID=8YFLogxK

U2 - 10.3390/ph3082441

DO - 10.3390/ph3082441

M3 - Review article

VL - 3

SP - 2441

EP - 2469

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 8

ER -